Fructooligosaccharide associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats
- PMID: 14971826
- DOI: 10.1051/rnd:2003028
Fructooligosaccharide associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats
Abstract
According to Burkitt's hypothesis, dietary fibres may protect against the development of colorectal cancer. In rats, studies have shown that only butyrate-producing fibres are protective. In parallel, in humans, non-steroidal anti-inflammatory drugs, which target cyclooxygenases, have been shown to display a protective effect against colorectal cancer. Among them, COX-2-selective inhibitors which present less side effects than non-selective agents, are promising as chemopreventive agents. Our aim was to analyse the effect of an association between butyrate-producing fibres and the COX-2 inhibitor on the development of aberrant crypt foci (ACF) in rats. Fisher F344 rats were fed with (1) a standard low fibre control diet; (2) the standard diet supplemented with 1500 ppm celecoxib; (3) a diet supplemented with 6% fructo-oligosaccharide (FOS); and (4) a diet with both celecoxib and FOS. Three weeks later, the rats were injected twice with azoxymethane and the number of ACF was determined 15 weeks later. In the control group, 43.8 +/- 6.4 ACF were found. This number was not significantly modified by the addition of FOS or celecoxib alone to the diet. However, the association of FOS and celecoxib resulted in a 61% reduction in the number of ACF (P < 0.01). The number of aberrant crypt per foci was also reduced. Thus, although no significant effect of celecoxib or FOS alone was identified, the association of butyrate-producing fibre and celecoxib was effective in preventing the development of ACF. This preliminary study argues for a strong protective effect of such an association which deserves further studies.
Similar articles
-
Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.Cancer Res. 2002 Jan 1;62(1):165-70. Cancer Res. 2002. PMID: 11782374
-
Only fibres promoting a stable butyrate producing colonic ecosystem decrease the rate of aberrant crypt foci in rats.Gut. 2001 Jan;48(1):53-61. doi: 10.1136/gut.48.1.53. Gut. 2001. PMID: 11115823 Free PMC article.
-
Effect of concomitant polyethylene glycol and celecoxib on colonic aberrant crypt foci and tumors in F344 rats.Dig Dis Sci. 2005 Jul;50(7):1304-11. doi: 10.1007/s10620-005-2777-4. Dig Dis Sci. 2005. PMID: 16047477
-
Chemoprophylaxis of colon cancer.Curr Gastroenterol Rep. 2005 Oct;7(5):389-95. doi: 10.1007/s11894-005-0009-x. Curr Gastroenterol Rep. 2005. PMID: 16168238 Review.
-
Nutritional targeting of cyclooxygenase-2 for colon cancer prevention.Inflamm Allergy Drug Targets. 2010 Jul;9(3):181-91. doi: 10.2174/187152810792231922. Inflamm Allergy Drug Targets. 2010. PMID: 20553228 Review.
Cited by
-
Galacto-oligosaccharides and Colorectal Cancer: Feeding our Intestinal Probiome.J Funct Foods. 2015 Jan;12:92-108. doi: 10.1016/j.jff.2014.10.029. J Funct Foods. 2015. PMID: 25584074 Free PMC article.
-
Prebiotics: Ignored player in the fight against cancer.Cancer Rep (Hoboken). 2023 Nov;6(11):e1870. doi: 10.1002/cnr2.1870. Epub 2023 Jul 17. Cancer Rep (Hoboken). 2023. PMID: 37458148 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials